Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dark

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Physiology & Behavior|August 1, 1977
Active avoidance in rats with unilateral hypothalamic and optic nerve lesionsD Asdourian, J G Dark, L Chiodo, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|August 24, 2016
Impact of a 2-Week Oncology Placement on Medical Students' Perception of CancerJonathan Mayes, Simon Davies, Andrew Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Surveillance policy for stage I ovarian germ cell tumorsG G Dark, M Bower, E S Newlands, et al.
Physiology & Behavior|September 1, 1977
Impairment in a T-maze task following unilateral lateral hypothalamic lesionsJ G Dark, L A Chiodo, P S Papich, et al.
Cancer Research|May 15, 1997
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculatureG G Dark, S A Hill, V E Prise, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|June 12, 2014
Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancerN Mirbagheri, B Kumar, S Deb, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumoursH Bourgeois, J Vermorken, G Dark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Differentiation and definition of vascular-targeted therapiesDietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)R Booton, P Lorigan, H Anderson, et al.
Gynecologic Oncology|September 23, 2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Physiology & Behavior|August 1, 1977
Active avoidance in rats with unilateral hypothalamic and optic nerve lesionsD Asdourian, J G Dark, L Chiodo, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|August 24, 2016
Impact of a 2-Week Oncology Placement on Medical Students' Perception of CancerJonathan Mayes, Simon Davies, Andrew Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Surveillance policy for stage I ovarian germ cell tumorsG G Dark, M Bower, E S Newlands, et al.
Physiology & Behavior|September 1, 1977
Impairment in a T-maze task following unilateral lateral hypothalamic lesionsJ G Dark, L A Chiodo, P S Papich, et al.
Cancer Research|May 15, 1997
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculatureG G Dark, S A Hill, V E Prise, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|June 12, 2014
Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancerN Mirbagheri, B Kumar, S Deb, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumoursH Bourgeois, J Vermorken, G Dark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Differentiation and definition of vascular-targeted therapiesDietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)R Booton, P Lorigan, H Anderson, et al.
Gynecologic Oncology|September 23, 2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.
Pageof 3